Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0344307 (analgesia)
 28,200 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effects of angiotensin II (A II), bombesin (B) and naloxone (N) on the amplitude of the late component of the evoked potentials of the cortex (EP) were studied by electrocutaneous (ECS) and tooth pulp (ETS) stimulation. An intraventricular (50 ng/kg) or intravenous (5 micrograms/kg) injections decreased the amplitude of the negative-positive component with a 20-40 ms latency (NP20-40) EP to ETS, but not to ECS. Saralasin (A II antagonist) injected intraventricularly (130 ng/kg) abolished this effect of A II in response to ETS. N intraventricular injections (30 micrograms/kg) increased the amplitude of NP20-40 EP to ETS, but not to ECS. B (intraventricular injection 20 ng/kg decreased the amplitude of NP20-40 EP to ECS, but not to ETS. This suggests there are the specific mechanisms in analgesia induced by A II and B in the pathways activated by ECS and ETS.
 ...
PMID:Angiotensin II, bombesin and naloxone in tooth pulp and cutaneous nociceptive mechanisms in rabbits. 297 96